Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.44 |
| ▸ | PRKCI | P41743 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351992 | 0.86 | ADORA1 (0.82) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL3499018 | 0.86 | ADORA1 (1.00) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL20665903 | 0.84 | ADORA1 (0.61) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL13739529 | 0.84 | ADORA1 (0.78) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL2643671 | 0.84 | MAPT (0.73) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL17018795 | 0.82 | ADORA1 (0.65) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL938054 | 0.81 | ADORA1 (1.00) | ADORA1KDM4EMAPTGAA | |
| SCHEMBL4065123 | 0.80 | MAPT (0.81) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL21726131 | 0.79 | ADORA1 (0.64) | ADORA1KDM4EMAPTGAANR1H2 | |
| SCHEMBL135453 | 0.79 | KDM4E (0.83) | ADORA1KDM4EMAPTGAANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | PEKARI KLAUS | 2010-12-23 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7714135-B2 | Tetrahydropyridothiophenes for the treatment of proliferative diseases such as cancer | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | ALTANA PHARMA AG (DE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096914-A1 | Tetrahydropyridothiophenes for the Treatment of Proliferative Diseases Such as Cancer | MKI67, CCNT1, RB1 | ADORA1 4245/4885KDM4E 2213/4885MAPT 884/4885 |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | ADORA1 467/4885KDM4E 2617/4885MAPT 3736/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | ADORA1 3786/4885KDM4E 1697/4885MAPT 1276/4885 |
| US-20100324038-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | CCNT1, MALT1, CCNA1 | ADORA1 1878/4885KDM4E 2362/4885MAPT 3705/4885 |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | ADORA1 3786/4885KDM4E 1697/4885MAPT 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.